PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
74.40%
Cash & equivalents growing 74.40% while AGEN's declined -21.89%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
74.40%
Below half of AGEN's -21.89%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Above 1.5x AGEN's -13.73%. Michael Burry might investigate for potential short-term asset misclassification or risk.
70.82%
Below half of AGEN's -21.26%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Below half of AGEN's -30.42%. Michael Burry sees a potential red flag for stagnation or capital shortage.
72.56%
Less than half of AGEN's -27.47%. David Dodd sees a more disciplined AP approach or lower volume.
-50.51%
Less than half of AGEN's 1108.19%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.03%
Similar yoy changes to AGEN's 34.75%. Walter Schloss finds parallel near-term liability trends.
36.12%
1.25-1.5x AGEN's 24.21%. Martin Whitman is wary of bigger short-term burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.12%
Less than half of AGEN's -19.20%. David Dodd sees far fewer liability expansions relative to competitor.
10.25%
Similar yoy changes to AGEN's 13.14%. Walter Schloss sees parallel capital-raising strategies.
-4.93%
≥ 1.5x AGEN's -1.78%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
247.64%
≥ 1.5x AGEN's 23.90%. David Dodd sees stronger capital base growth than competitor.
70.82%
Below half AGEN's -30.42%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-50.51%
50-75% of AGEN's -74.60%. Bruce Berkowitz sees relatively smaller yoy debt additions.
-77.35%
50-75% of AGEN's -122.02%. Bruce Berkowitz notes comparatively lower net debt expansion.